Compare Johnson Controls International PLC (JCI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs ResMed Inc. — how do they compare? Johnson Controls International PLC trades at $157.62 (market cap $93.28B), while ResMed Inc. trades at $231.16 (market cap $31.89B). The key difference: Johnson Controls International PLC is far larger — about 2.9× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson Controls International PLC for 65 Days and ResMed Inc. for 51 Days on average.
| JCI | RMD | |
|---|---|---|
Market Cap | $93.28B | $31.89B |
Volume | 2,786,476 | 618,314 |
Sector | Basic Materials | Health |
52-Week High | $158.76 | $277.88 |
52-Week Low | $105.55 | $182.82 |
Typical Hold Time | 65 Days | 51 Days |
Enterprise Value | $102.12B | $31.24B |
Dividend Yield | 1.04% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson Controls International (JCI) trades at $157.46, up 0.98% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS beating estimates at $1.42 versus $1.30 expected, and revenue growth accelerating to 9% in Q3 2026. Valuation metrics remain elevated with P/E at 43.38, but profitability is strong with net income margin of 14.32% and ROE of 24.42%.
JCI presents a favorable investment case with consistent earnings beats, raised FY26 guidance, and strong institutional support. Key risks include high valuation multiples and increasing debt-to-asset ratio reaching 26.06% in 2025. The consensus price target of $172.50 suggests 9.6% upside potential from current levels, supported by 28 buy ratings and no sell recommendations from analysts.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
